Table 2.
Clinical data on disease severity
| Patient | MDS-UPDRS (Part III) | H&Y Stage | PIGD Sum Items 3.7–3.17 | FoG Ziegler score | LEDD | MoCA |
|---|---|---|---|---|---|---|
| 1 | 45 | 2 | 8 | 7 | 1834.8 | 23 |
| 2 | 28 | 2 | 6 | 9 | 2200 | 24 |
| 3 | 35 | 3 | 11 | 0 | 1050 | 28 |
| 4 | 40 | 3 | 8 | 0 | 1432.5 | 26 |
| 5 | 27 | 2 | 9 | 12 | 1350 | 26 |
| 6 | 33 | 3 | 12 | 0 | 1150 | 22 |
| 7 | 28 | 3 | 11 | 4 | 1600 | 28 |
| 8 | 26 | 3 | 11 | 14 | 1520 | 23 |
| 9 | 32 | 2 | 1 | 11 | 880 | 25 |
| 10 | 21 | 3 | 7 | 1 | 1225 | 24 |
| 11 | 62 | 2 | 11 | 11 | 885.6 | 15 |
| 12 | 22 | 3 | NA | NA | 1800 | 27 |
| 13 | 39 | 3 | 16 | NA | 1171.2 | 23 |
| 14 | 52 | 3 | 12 | 11 | 2022.5 | 26 |
| 15 | 46 | 2 | 9 | 11 | 942.4 | 29 |
| 16 | 42 | 2 | 11 | 0 | 1176.5 | 29 |
| 17 | 37 | 2 | 9 | 0 | 1350 | 25 |
| 18 | 59 | 3 | 16 | 23 | 1670 | 29 |
| 19 | 40 | 3 | 20 | 0 | 692.4 | 26 |
| 20 | 28 | 2 | 15 | 12 | 1025 | 25 |
| 21 | 35 | 3 | 9 | 22 | 1192.4 | 29 |
| 22 | 30 | 2 | 5 | 8 | 1410 | 24 |
| 23 | 31 | 2 | 14 | 0 | 1124.2 | 29 |
| 24 | 37 | 3 | 11 | 20 | 1787.5 | 24 |
| 25 | 29 | 2 | 7 | 8 | 1180 | 25 |
| 26 | 36 | 2 | 8 | 4 | 1253 | 30 |
| 27 | 21 | 2 | 7 | 0 | 1342.4 | 30 |
| 28 | 27 | 2 | 5 | 2 | 1287 | 29 |
| 29 | 22 | 2 | 2 | 5 | 1181.2 | 23 |
Examination performed in the off phase. MDS-UPDRS (MDS-Unified Parkinson’s Disease Rating Scale) Part III: 21–62 (mean: 34.83, median: 43.00, SD: 10.54) – rated by the same physician; Hoehn and Yahr Stage (H&Y): range 2–3, mode: 2 19%: 81%; Postural Instability and Gait Disorder (PIGD) Questionnaire Items 3.7-3.13 Score: 1–20 (mean: 9.68, median: 9.00, SD: 4.21), Ziegler Score: 0–23 (mean: 7.22, median: 7.00, SD: 7.05), Levodopa Equivalence Dose (LEDD): 1150–1520 (mean: 1335.7, median: 1253.0, SD: 353.4), MoCA (Montreal Cognitive Assessment): 15–30 (mean: 25.52, median: 25, SD: 3.19), NA: not available.